Esperion Therapeutics | ESPR - Ebitda


Esperion Therapeutics reported $-27.51M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Cipla INR 12.55B 6.4B Dec/2025
CSL USD 1.96B 1.27B Jun/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Geron USD -7.55M 8.85M Jun/2025
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 248.25M 22.74M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -208M 552M Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024